Generation Bio Co (NASDAQ:GBIO)’s traded shares stood at 0.35 million during the last session, with the company’s beta value hitting 2.68. At the close of trading, the stock’s price was $1.07, to imply a decrease of -3.60% or -$0.04 in intraday trading. The GBIO share’s 52-week high remains $4.65, putting it -334.58% down since that peak but still an impressive 29.91% since price per share fell to its 52-week low of $0.75. The company has a valuation of $71.47M, with an average of 0.62 million shares in intraday trading volume over the past 10 days and average of 231.15K shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Generation Bio Co (GBIO), translating to a mean rating of 1.86. Of 1 analyst(s) looking at the stock, 0 analyst(s) give GBIO a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 1 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -0.23.
Generation Bio Co (NASDAQ:GBIO) trade information
After registering a -3.60% downside in the last session, Generation Bio Co (GBIO) has traded red over the past five days. The 5-day price performance for the stock is -0.93%, and -25.69% over 30 days. With these gigs, the year-to-date price performance is -35.15%. Short interest in Generation Bio Co (NASDAQ:GBIO) saw shorts transact 1.53 million shares and set a 8.96 days time to cover.
Generation Bio Co (GBIO) estimates and forecasts
Looking at statistics comparing Generation Bio Co share performance against respective industry, we note that the company has underperformed competitors. Generation Bio Co (GBIO) shares are -62.06% down over the last 6 months, with its year-to-date growth rate lower than industry average at 10.71% against 16.60%. The rating firms project that company’s revenue will grow 207.23% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 2.92M. Meanwhile, for the current quarter, a total of 4 analyst(s) estimate revenue growth to 1.4M.Earnings reports from the last fiscal year show that sales brought in 2.88M and 4.06M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 1.35% before dropping -65.51% in the following quarter.
GBIO Dividends
Generation Bio Co has its next earnings report out in January. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Generation Bio Co (NASDAQ:GBIO)’s Major holders
Generation Bio Co insiders hold 14.51% of total outstanding shares, with institutional holders owning 82.94% of the shares at 97.02% float percentage. In total, 82.94% institutions holds shares in the company, led by PRICE T ROWE ASSOCIATES INC /MD/. As of 2024-06-30, the company held over 9.51 million shares (or 14.3205% of shares), all amounting to roughly $26.83 million.
The next major institution holding the largest number of shares is ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC with 8.28 million shares, or about 12.4628% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $23.35 million.
We also have Price (T.Rowe) New Horizons Fund and Fidelity Growth Company Fund as the top two Mutual Funds with the largest holdings of the Generation Bio Co (GBIO) shares. Going by data provided on Sep 30, 2024 , Price (T.Rowe) New Horizons Fund holds roughly 5.34 shares. This is just over 8.00% of the total shares, with a market valuation of $5.72 million. Data from the same date shows that the other fund manager holds a little less at 1.82, or 2.72% of the shares, all valued at about 1.95 million.
